specif
pathogen
free
kitten
werevaccin
unattenu
field
isol
canin
coronaviru
ccv
either
aerosol
subcutan
receiv
boost
vaccin
four
week
later
aerosolis
elicit
homolog
virusneutralis
vn
antibodi
respons
increas
steadili
fourweek
period
level
one
two
week
revaccin
initi
aerosolis
dose
produc
asymptomat
infect
excret
eev
oropharynx
eight
day
vaccin
viru
shed
detect
howev
second
inocul
cat
vaccin
subcutan
develop
low
vn
antibodi
titr
first
eev
dose
experienc
strong
anamnest
respons
second
dose
neutralls
antibodi
titr
level
one
two
week
revaccin
mean
valu
somewhat
lower
cat
vaccin
aerosol
eev
isol
oropharynx
either
subcutan
dose
four
week
eev
boost
inocul
vaccin
cat
shamvaccin
control
cat
divid
three
subgroupsnd
challeng
aerosol
withth
virul
ucm
strain
felin
infecti
periton
viru
fipv
ucm
three
differ
dosag
level
five
six
cat
includ
shamvaccin
control
given
lowest
challeng
dose
show
sign
diseas
cat
develop
lesion
typic
felin
infecti
periton
fip
five
surviv
cat
develop
fip
subsequ
challeng
fivefold
higher
dose
thu
heterotyp
vaccin
cat
eev
provid
effect
protect
fipv
challeng
felin
infecti
periton
viru
flpv
member
famili
coronavirida
import
pathogen
domest
exot
cat
barlough
weiss
barlough
stoddart
scott
pedersen
caus
agent
lethal
immunolog
mediat
vascul
felin
infecti
address
oklahoma
anim
diseas
diagnost
laboratori
colleg
veterinari
medicin
oklahoma
state
univers
stillwat
oklahoma
usa
periton
flp
characteris
fibrin
periton
pleuriti
format
dissemin
pyogranuloma
current
therapi
usual
consist
corticosteroid
potent
cytoreduct
drug
palli
natur
instanc
ineffect
halt
relentlessli
progress
cours
diseas
safe
effect
fip
vaccin
yet
develop
experi
thu
far
report
use
variou
virus
within
fipv
antigen
cluster
pedersen
et
al
success
confer
uniformli
protect
immun
toma
et
al
wood
pedersen
pedersen
et
al
pedersen
black
barlough
et
al
pedersen
floyd
paradox
immunopatholog
natur
diseas
vaccin
felin
coronavirus
actual
predispos
cat
develop
fip
produc
rapid
fulmin
diseas
flpv
challeng
heterotyp
vaccin
use
cross
reactiv
coronavirus
transmiss
gastroenter
viru
tgev
pig
canin
coronaviru
lccvl
r
human
coronaviru
neither
sensitis
protect
cat
experi
mechan
sensitis
immun
flp
incomplet
understood
present
may
suppos
mani
viru
infect
properli
balanc
cellmedi
immun
respons
involv
lymphocyt
natur
killer
cell
activ
macrophag
essenti
effect
host
resist
earlier
pilot
studi
barlough
et
author
demonstr
ccv
capabl
infect
cat
antibodi
elicit
multipl
daili
oronas
dose
viru
could
cross
react
commerci
avail
coronaviru
antibodi
test
use
tgev
target
antigen
vaccin
ccv
produc
clinic
sign
infect
result
excret
detect
viru
faec
protect
cat
fipv
challeng
number
cat
use
first
studi
small
howev
larg
challeng
dose
fipv
investig
larger
studi
use
greater
number
cat
undertaken
vaccin
aerosol
subcutan
rout
assay
viru
excret
oropharynx
challeng
three
differ
dose
fipv
dose
use
pilot
studi
result
comprehens
vaccin
trial
subject
present
commun
eighteen
specif
pathogen
free
kitten
nine
femal
nine
male
purchas
liberti
laboratori
hous
singli
negativepressur
fibreglass
isol
cage
special
equip
maxim
air
exchang
cat
commerci
breed
coloni
free
serum
coronaviru
antibodi
felin
leukaemia
viru
felin
viru
infect
vaccin
felin
panleucopenia
inactiv
vaccin
strict
isol
procedur
care
anim
throughout
experi
minimis
possibl
viru
contamin
group
vaccin
shamvaccin
control
cat
care
altern
day
two
adult
coronaviru
antibodyneg
cat
obtain
previous
breed
coloni
use
sentinel
room
control
clone
stock
karbatsch
isol
ccv
propag
canin
describ
previous
barlough
et
viru
origin
isol
march
faec
dog
enter
l
e
carmichael
univers
person
commun
virul
strain
flpv
fipv
ucdi
pedersen
prepar
liver
homogen
per
cent
concentr
cultur
medium
passag
specif
pathogen
free
cat
homogen
centrifug
g
minut
supernat
pool
store
use
challeng
inocula
previou
similar
prepar
weiss
determin
contain
approxim
infect
dose
ml
four
concentr
homogen
per
cent
per
cent
per
cent
per
cent
leibovitz
medium
gibcol
use
studi
viru
neutralis
vn
test
use
ccv
karbatsch
perform
essenti
describ
barlough
et
al
minor
modif
coronaviru
antibodi
titr
also
determin
computerassist
kineticsbas
enzymelink
immunosorb
assay
kela
use
tgev
antigen
describ
previous
barlough
et
al
barlough
et
al
oropharyng
swab
sampl
elut
individuallyin
ml
medium
store
upon
thaw
ml
sampl
ad
quadrupl
grown
plate
costar
monolay
observ
seven
day
develop
characterist
syncyti
cytopath
effect
ccv
karbatsch
barlough
et
cytopath
effect
evid
within
two
day
inocul
posit
sampl
specif
pathogen
free
cat
divid
five
experiment
group
shown
tabl
day
cat
group
vaccin
either
ccv
vaccin
cat
uninfect
cultur
fluid
supernat
shamvaccin
control
cat
cat
group
given
ml
cultur
supernat
contain
x
ccv
aerosolis
procedur
describ
previous
scott
barlough
et
al
briefli
cat
confin
within
plastic
anaesthet
chamber
searl
industri
aerosolis
perform
fineparticl
nebulis
hoechstroussel
pharmaceut
psi
minut
cat
remain
nebulis
fog
addit
minut
remov
chamber
cat
group
inocul
singl
subcutan
inject
cervic
region
ml
cultur
supernat
contain
x
ccv
cat
group
shamvaccin
uninfect
cultur
supernat
aerosol
subcutan
rqpte
respect
cat
group
maintain
sentinel
room
control
expos
ccv
fipv
uninfect
cultur
supernat
day
four
week
second
vaccin
cat
group
challeng
fipv
ucdi
aerosol
accord
scheme
illustr
tabl
three
concentr
liver
homogen
employ
per
cent
per
cent
per
cent
aerosolis
perform
describ
vaccin
use
ml
appropri
fipv
prepar
amount
viru
deliv
calcul
respect
three
homogen
concentr
cat
surviv
lowest
flpv
challeng
dose
rechalleng
day
week
first
per
cent
liver
homogen
prepar
contain
approxim
cat
monitor
daili
clinic
sign
arrow
indic
inocul
ccv
karbatsch
fipv
latter
repres
day
lethal
challeng
subgroup
c
cat
surviv
time
interv
first
fipv
challeng
second
lethal
challeng
shown
data
challeng
repres
synchronis
respons
fipv
aerosol
ccv
group
subcutan
ccv
group
shamvaccin
control
group
sentinel
room
control
group
shown
oropharyng
swab
sampl
ccv
isol
collect
variabl
interv
rang
daili
weekli
vaccin
portion
experi
blood
sampl
coronaviru
antibodi
detect
obtain
weekli
jugular
venipunctur
cat
given
fipv
human
kill
becam
moribund
intracardiac
administr
euthanasia
solut
r
nation
laboratori
initi
anaesthesia
ketamin
hydrochlorid
tissu
collect
histopatholog
examin
order
confirm
clinic
diagnosi
clinic
observ
room
control
cat
group
continu
sever
month
termin
experi
differ
mean
surviv
time
lethal
fipv
challeng
test
signific
mannwhitney
rank
sum
method
unpair
measur
snedecor
cochran
respons
challeng
tabl
cat
given
two
larger
dose
fipv
subgroup
b
develop
clinic
sign
fip
diagnosi
confirm
histopatholog
examin
tissu
death
five
six
cat
given
smallest
challeng
dose
per
cent
liver
homogen
subgroup
c
remain
healthi
sixth
vaccin
ccv
subsign
fip
remain
healthi
throughout
cours
experi
develop
extrem
low
vn
titr
first
detect
two
week
vaccin
tit
re
rose
margin
succeed
two
week
boost
high
level
second
vaccin
reach
plateau
mean
valu
neutralis
antibodi
titr
individu
cat
remain
rel
stabl
fipv
challeng
shamvaccin
cat
group
consist
neg
ccv
vn
test
fipv
challeng
extrem
low
level
heterotyp
vn
antibodi
detect
termin
two
subgroup
c
cat
second
lethal
challeng
crossreact
antibodi
tgev
detect
cat
lethal
fipv
challeng
fig
rapid
dramat
rise
kela
titr
occur
aerosolvaccin
cat
group
challeng
perhap
reflect
product
nonneutralis
antibodi
barlough
et
two
cat
surviv
lowest
fipv
challeng
dose
subgroup
c
develop
kela
titr
second
lethal
challeng
antibodi
tgev
detect
two
subcutan
vaccin
cat
group
challeng
one
surviv
subgroup
c
cat
develop
kela
titr
second
lethal
fipv
challeng
sever
cat
given
subcutan
inocul
develop
elev
background
reactiv
serum
detect
kela
reactiv
associ
previous
humor
immun
respons
extran
noncoronavir
compon
cell
cultur
medium
barlough
et
al
shamvaccin
cat
group
remain
neg
kela
fipv
challeng
sentinel
room
control
cat
seroneg
assay
throughout
cours
experi
data
shown
virusneutralis
antibodi
titr
ccv
vaccin
challeng
shown
fig
cat
vaccin
ccv
aerosol
group
develop
vn
antibodi
titr
first
detect
two
week
vaccin
rose
steadili
succeed
two
week
less
dramat
increas
occur
second
ccv
vaccin
tit
re
level
mean
valu
heterotyp
vn
anamnest
respons
seen
fipv
challeng
instead
titr
level
individu
cat
remain
stabl
death
group
group
two
cat
subcutan
vaccin
group
group
tabl
four
cat
aerosol
group
shed
viru
oropharynx
eight
day
first
vaccin
shed
occur
howev
second
ccv
vaccin
two
cat
subcutan
group
shed
detect
amount
ccv
either
vaccin
recognis
antigen
cross
reactiv
fipv
ccv
origin
prompt
author
examin
potenti
ccv
protect
cat
virul
fipv
challeng
earlier
pilot
studi
barlough
et
al
two
cat
vaccin
ccv
karbatsch
oronas
challeng
larg
dose
approxim
fipv
ucdl
aerosol
cat
succumb
fip
mean
surviv
time
day
shamvaccin
control
cat
experienc
similar
diseas
cours
mean
surviv
time
day
felin
coronaviru
antibodysensitis
control
cat
howev
die
day
challeng
p
therefor
conclud
vaccin
cat
ccv
sensitis
develop
acceler
fip
subsequ
fipv
exposur
expand
studi
report
perform
evalu
fulli
potenti
ccv
heterotyp
immunogen
fip
cat
vaccin
ccv
aerosol
induc
potenti
protect
mucos
immun
aerosol
challeng
oronas
vaccin
use
pilot
studi
addit
lower
grade
challeng
dose
fipv
use
possibl
howev
demonstr
convinc
protect
even
lowest
fipv
challeng
dose
thu
appear
vaccin
cat
ccv
confer
protect
fipv
although
initi
seem
five
six
cat
receiv
lowest
fipv
dose
subgroup
c
resist
challeng
second
challeng
viru
show
immun
like
explan
five
cat
receiv
infect
dose
fipv
initi
aerosol
challeng
view
support
three
observ
characterist
kela
respons
ccvvaccin
cat
termin
ccv
vn
respons
shamvaccin
cat
appear
second
lethal
flpv
challeng
dose
ii
evolut
immun
respons
surviv
shamvaccin
cat
primari
rather
anamnest
iii
absenc
sensitis
five
cat
indic
mean
surviv
time
infect
fipv
ucdi
initi
challeng
dose
would
sensitis
cat
second
flpv
ucdi
challeng
rapid
fulmin
fip
diseas
cours
would
ensu
barlough
et
al
present
experi
document
ccv
shed
cat
first
time
cat
vaccin
aerosol
shown
excret
ccv
oropharynx
eight
day
inocul
follow
revaccin
ccv
howev
viru
shed
occur
suggest
cat
immunis
ccv
unfortun
immun
heterotyp
extend
fipv
vn
antibodi
respons
elicit
first
ccv
aerosol
vaccin
increas
steadili
succeed
four
week
manner
suggest
vivo
amplif
inocul
dose
fig
mim
result
also
obtain
earlier
pilot
studi
support
pattern
ccv
excret
oropharynx
tabl
consid
togeth
appar
absenc
shed
follow
boost
ccv
vaccin
would
appear
limit
replic
ccv
occur
aerosolvaccin
cat
cat
degre
immunis
subsequ
ccv
infect
contrast
subcutan
inocul
cat
ccv
elicit
initi
low
level
vn
respons
boost
consider
revaccin
data
indic
anamnest
respons
inert
immunogen
mim
suggest
littl
replic
ccv
cat
vaccin
subcutan
unlik
author
earlier
studi
ccvvaccin
elicit
crossreact
antibodi
tgev
detect
kela
previou
experi
howev
cat
develop
kela
titr
repeat
daili
oronas
administr
ccv
initi
two
dose
descr
jbed
previous
barlough
et
al
phenomenon
attribut
two
factor
first
administr
qf
low
dose
coronavirus
result
product
neutralis
antibodi
direct
viral
peplom
higher
dose
result
addit
antibodi
nonpeplom
determin
nonneutralis
second
neutralis
antipeplom
antibodi
detect
vn
perhap
kela
due
loss
antigen
alter
fragil
peplom
tgev
antigen
prepar
cat
present
experi
may
given
dose
ccv
suffici
produc
detect
nonpeplom
anti
bodi
thu
remain
neg
kela
lethal
flpv
challeng
dramat
anamnest
respons
aerosolvaccin
cat
suggest
prime
immun
respons
nonpeplom
determin
challeng
meagr
kela
respons
subcutan
vaccin
cat
challeng
may
reflect
smaller
degre
prime
attribut
littl
ccv
replic
pilot
studi
shamvaccin
cat
remain
neg
kela
even
lethal
fipv
challeng
author
often
encount
absenc
kela
respons
tgev
coronavirusna
cat
experiment
fipv
challeng
probabl
due
combin
induct
primari
rather
anamnest
immun
respons
swiftli
fatal
experiment
diseas
cours
immun
complex
format
lesser
sensit
heterolog
assay
studi
confirm
earlier
find
ccvvaccin
cat
sensitis
fipv
previou
studi
shown
cat
preexist
coronaviru
antibodi
challeng
fipv
develop
rapid
fulmin
form
diseas
seroneg
cat
similarli
challeng
toma
et
pedersen
boyl
weiss
et
pedersen
et
weiss
weiss
scott
pedersen
black
barlough
et
al
pedersen
floyd
felin
coronaviru
strain
appear
predomin
sensitis
coronavirus
neither
tgev
human
coronaviru
ccv
produc
signific
sensitis
experi
report
thu
far
sensitis
appear
coronaviru
strainspecif
depend
ident
sensitisingviru
also
challeng
strain
sensitis
phenomenon
prove
one
major
impedi
develop
safe
effect
fip
vaccin
thu
hope
nonsensitis
crossreact
coronaviru
ccv
might
abl
provid
immun
without
sensitis
date
howev
strategi
met
success
mechan
govern
immun
fip
remain
larg
unidentifi
result
work
carri
past
decad
suggest
howev
humor
immun
respons
probabl
minor
signific
sensitis
natur
may
even
detriment
host
report
fip
immunis
attempt
recent
experi
perform
laboratori
vaccin
cat
respond
unpredict
idiosyncrat
virul
fipv
challeng
protect
often
allornoth
phenomenon
wherein
cat
protect
yet
other
complet
resist
ident
challeng
dose
administ
ident
manner
opinion
fundament
studi
virushost
interact
mechan
govern
immun
fipv
must
perform
guidelin
realist
immunis
strategi
sketch
